published meta-analysis   sensitivity analysis   studies

colchicine in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] COLCOVID, 2021 0.88 [0.70; 1.11] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36] Horby, 2021 1.01 [0.93; 1.10] RECOVERY (colchicine), 2021 1.01 [0.93; 1.10] 1.00[0.94; 1.06]COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Horby, 2021, RECOVERY (colchicine), 202150%24,376moderateserious deathsdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] COLCOVID, 2021 0.88 [0.70; 1.11] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36] GRECCO-19, 2020 0.21 [0.02; 1.97] Horby, 2021 1.01 [0.93; 1.10] RECOVERY (colchicine), 2021 1.01 [0.93; 1.10] Salehzadeh, 2020 1.00 [0.02; 51.41] 1.00[0.94; 1.06]COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, Horby, 2021, RECOVERY (colchicine), 2021, Salehzadeh, 202070%24,581moderateserious deaths (time to event analysis only)detailed resultsCOLCOVID, 2021 0.88 [0.70; 1.11] 0.88[0.70; 1.11]COLCOVID, 202110%1,279NAnot evaluable clinical deteriorationdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58] GRECCO-19, 2020 0.11 [0.01; 1.08] 0.27[0.08; 0.90]COL-COVID (Pascual-Figal), 2021, GRECCO-19, 202020%208moderatenot evaluable death or ventilationdetailed resultsCOLCOVID, 2021 0.83 [0.67; 1.02] RECOVERY (colchicine), 2021 1.02 [0.96; 1.09] 0.94[0.78; 1.15]COLCOVID, 2021, RECOVERY (colchicine), 2021270%12,090moderatenot evaluable hospital dischargedetailed resultsRECOVERY (colchicine), 2021 0.98 [0.94; 1.03] 0.98[0.94; 1.03]RECOVERY (colchicine), 202110%11,340NAnot evaluable mechanical ventilationdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06] GRECCO-19, 2020 0.17 [0.02; 1.48] RECOVERY (colchicine), 2021 1.04 [0.93; 1.16] 0.93[0.73; 1.18]COL-COVID (Pascual-Figal), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, RECOVERY (colchicine), 2021449%11,295moderatenot evaluable ICU admissiondetailed resultsCOL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75] 0.92[0.54; 1.58]COL-COVID (Pascual-Figal), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 202120%330moderatenot evaluable serious adverse eventsdetailed resultsCOL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] 0.24[0.01; 5.41]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable adverse eventsdetailed resultsCOL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08] 1.72[0.73; 4.08]COL-COVID (Pascual-Figal), 202110%103NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-28 09:52 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 560,1102 - roots T: 290